

Supplementary Table 1. Characteristics of the accrued patients who were included in the final analysis as compared to the superset of patients who were clinically eligible for inclusion.

	Evaluable patients in final analysis (n=262)		Clinically eligible patients (n=335)	
	No. patients	%	No. patients	%
Age (years)				
< 50	38	(14.5)	47	(14.0)
50 – 59	79	(30.2)	101	(30.2)
60 – 69	80	(30.5)	109	(32.5)
≥ 70	65	(24.8)	77	(23.0)
Unknown	-	-	1	(0.3)
Median (range)	61 (24-93)		62 (24-93)	
Race				
Caucasian	234	(89.3)	290	(86.6)
African American	14	(5.3)	18	(5.4)
Others	14	(5.3)	20	(6.0)
Unknown	-	-	7	(2.1)
ECOG Performance Status				
0	183	(69.9)	239	(71.3)
1	66	(25.2)	79	(23.6)
2	13	(5.0)	16	(4.8)
Unknown	-	-	1	(0.3)
Histology				
Serous	178	(67.9)	226	(67.5)
Endometrioid	19	(7.3)	25	(7.5)
Clear cell	19	(7.3)	23	(6.9)
Mucinous	3	(1.3)	3	(0.9)
Adenocarcinoma, NOS	30	(11.5)	36	(10.8)
Others	13	(5.0)	21	(6.3)
Unknown	-	-	1	(0.3)
Tumor Grade				
1	12	(4.6)	18	(5.4)
2	33	(12.6)	38	(11.3)
3	168	(64.1)	215	(64.2)
Unknown	49	(18.7)	64	(19.1)
Platinum Sensitivity Status*				
Platinum-sensitive	145	(55.3)	159	(56.2)
Platinum-resistant	117	(44.7)	124	(43.8)

*Platinum sensitivity status was not collected for some clinically eligible patients whose assay results were not evaluable.